Remove trial restrictions ▶ Start for $1

Serving leading biopharmaceutical companies globally:

Baxter
McKinsey
Mallinckrodt
Express Scripts
Harvard Business School
Moodys

Last Updated: August 14, 2022

KYNMOBI Drug Patent Profile


✉ Email this page to a colleague

« Back to Dashboard

▶ Start for $1
Remove trial restrictions


Which patents cover Kynmobi, and what generic alternatives are available?

Kynmobi is a drug marketed by Sunovion Pharms Inc and is included in one NDA. There are eighteen patents protecting this drug.

This drug has two hundred and forty-nine patent family members in twenty-five countries.

The generic ingredient in KYNMOBI is apomorphine hydrochloride. There are six drug master file entries for this compound. Three suppliers are listed for this compound. Additional details are available on the apomorphine hydrochloride profile page.

US Patents and Regulatory Information for KYNMOBI

KYNMOBI is protected by eighteen US patents and one FDA Regulatory Exclusivity.

Patents protecting KYNMOBI

Sublingual apomorphine
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
Patented Use: TREATMENT OF 'OFF' EPISODES IN PATIENTS WITH PARKINSON'S DISEASE

Methods of treating parkinson's disease by administration of apomorphine to an oral mucosa
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
Patented Use: TREATMENT OF 'OFF' EPISODES IN PATIENTS WITH PARKINSON'S DISEASE

Sublingual and buccal film compositions
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing

Thin film with non-self-aggregating uniform heterogeneity and drug delivery systems made therefrom
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing

Methods of treating Parkinson's disease by administration of apomorphine to an oral mucosa
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
Patented Use: TREATMENT OF 'OFF' EPISODES IN PATIENTS WITH PARKINSON'S DISEASE

Uniform films for rapid-dissolve dosage form incorporating anti-tacking compositions
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing

Sublingual films
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
Patented Use: TREATMENT OF 'OFF' EPISODES IN PATIENTS WITH PARKINSON'S DISEASE

Uniform films for rapid dissolve dosage form incorporating taste-masking compositions
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing

Film compositions for delivery of actives
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing

Uniform films for rapid-dissolve dosage form incorporating anti-tacking compositions
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing

Sublingual films
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
Patented Use: TREATMENT OF 'OFF' EPISODES IN PATIENTS WITH PARKINSON'S DISEASE

Sublingual apomorphine
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing

Sublingual films
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
Patented Use: TREATMENT OF 'OFF' EPISODES IN PATIENTS WITH PARKINSON'S DISEASE

Sublingual apomorphine
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
Patented Use: TREATMENT OF 'OFF' EPISODES IN PATIENTS WITH PARKINSON'S DISEASE

Sublingual apomorphine
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
Patented Use: TREATMENT OF 'OFF' EPISODES IN PATIENTS WITH PARKINSON'S DISEASE

Sublingual apomorphine
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
Patented Use: TREATMENT OF 'OFF' EPISODES IN PATIENTS WITH PARKINSON'S DISEASE

Uniform films for rapid-dissolve dosage form incorporating anti-tacking compositions
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing

Uniform films for rapid dissolve dosage form incorporating taste-masking compositions
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing

FDA Regulatory Exclusivity protecting KYNMOBI

NEW PRODUCT
Exclusivity Expiration: See Plans and Pricing

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Sunovion Pharms Inc KYNMOBI apomorphine hydrochloride FILM;SUBLINGUAL 210875-004 May 21, 2020 RX Yes No See Plans and Pricing See Plans and Pricing See Plans and Pricing
Sunovion Pharms Inc KYNMOBI apomorphine hydrochloride FILM;SUBLINGUAL 210875-003 May 21, 2020 RX Yes No See Plans and Pricing See Plans and Pricing Y See Plans and Pricing
Sunovion Pharms Inc KYNMOBI apomorphine hydrochloride FILM;SUBLINGUAL 210875-002 May 21, 2020 RX Yes No See Plans and Pricing See Plans and Pricing Y See Plans and Pricing
Sunovion Pharms Inc KYNMOBI apomorphine hydrochloride FILM;SUBLINGUAL 210875-005 May 21, 2020 RX Yes Yes See Plans and Pricing See Plans and Pricing See Plans and Pricing
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for KYNMOBI

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Sunovion Pharms Inc KYNMOBI apomorphine hydrochloride FILM;SUBLINGUAL 210875-003 May 21, 2020 See Plans and Pricing See Plans and Pricing
Sunovion Pharms Inc KYNMOBI apomorphine hydrochloride FILM;SUBLINGUAL 210875-005 May 21, 2020 See Plans and Pricing See Plans and Pricing
Sunovion Pharms Inc KYNMOBI apomorphine hydrochloride FILM;SUBLINGUAL 210875-005 May 21, 2020 See Plans and Pricing See Plans and Pricing
Sunovion Pharms Inc KYNMOBI apomorphine hydrochloride FILM;SUBLINGUAL 210875-002 May 21, 2020 See Plans and Pricing See Plans and Pricing
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration

International Patents for KYNMOBI

When does loss-of-exclusivity occur for KYNMOBI?

Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:

Australia

Patent: 11343429
Estimated Expiration: See Plans and Pricing

Patent: 17200331
Estimated Expiration: See Plans and Pricing

Patent: 19200138
Estimated Expiration: See Plans and Pricing

Brazil

Patent: 2013015204
Estimated Expiration: See Plans and Pricing

Canada

Patent: 21756
Estimated Expiration: See Plans and Pricing

Patent: 15370
Estimated Expiration: See Plans and Pricing

Patent: 15378
Estimated Expiration: See Plans and Pricing

Patent: 16942
Estimated Expiration: See Plans and Pricing

China

Patent: 3476372
Estimated Expiration: See Plans and Pricing

Denmark

Patent: 51357
Estimated Expiration: See Plans and Pricing

Eurasian Patent Organization

Patent: 1156
Estimated Expiration: See Plans and Pricing

Patent: 1390855
Estimated Expiration: See Plans and Pricing

European Patent Office

Patent: 51357
Estimated Expiration: See Plans and Pricing

Patent: 35988
Estimated Expiration: See Plans and Pricing

Hong Kong

Patent: 93969
Estimated Expiration: See Plans and Pricing

Hungary

Patent: 49349
Estimated Expiration: See Plans and Pricing

Israel

Patent: 5936
Estimated Expiration: See Plans and Pricing

Japan

Patent: 86195
Estimated Expiration: See Plans and Pricing

Patent: 13545824
Estimated Expiration: See Plans and Pricing

Mexico

Patent: 13006911
Estimated Expiration: See Plans and Pricing

New Zealand

Patent: 2686
Estimated Expiration: See Plans and Pricing

Poland

Patent: 51357
Estimated Expiration: See Plans and Pricing

Portugal

Patent: 51357
Estimated Expiration: See Plans and Pricing

South Africa

Patent: 1304740
Estimated Expiration: See Plans and Pricing

South Korea

Patent: 1890317
Estimated Expiration: See Plans and Pricing

Patent: 1946774
Estimated Expiration: See Plans and Pricing

Patent: 2025238
Estimated Expiration: See Plans and Pricing

Patent: 2161392
Estimated Expiration: See Plans and Pricing

Patent: 140043051
Estimated Expiration: See Plans and Pricing

Patent: 180094143
Estimated Expiration: See Plans and Pricing

Patent: 190015597
Estimated Expiration: See Plans and Pricing

Patent: 190109598
Estimated Expiration: See Plans and Pricing

Spain

Patent: 91715
Estimated Expiration: See Plans and Pricing

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

See the table below for additional patents covering KYNMOBI around the world.

Country Patent Number Title Estimated Expiration
Canada 2468557 EMBALLAGE DESTINE DES COMPOSANTS ELECTRO-OPTIQUES (PACKAGE FOR ELECTRO-OPTICAL COMPONENTS) See Plans and Pricing
New Zealand 597237 Sublingual apomorphine See Plans and Pricing
South Korea 102161392 See Plans and Pricing
Japan 2018083820 舌下用アポモルフィン (SUBLINGUAL APOMORPHINE) See Plans and Pricing
>Country >Patent Number >Title >Estimated Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Merck
Johnson and Johnson
McKinsey
Baxter
McKesson
Express Scripts

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.